source
- NEJM retracts pivotal data for Amgen's Tavneos, adding new hurdle for the autoimmune drugThe New England Journal of Medicine has withdrawn the pivotal data that supported Amgen’s autoimmune therapy Tavneos. The retraction was requested by two academic authors who raised concerns about…
- Zymeworks CEO says $1 billion Theravance acquisition offers strong value despite recent setbacksZymeworks chief executive Kenneth Galbraith explained why the company believes its near-$1 billion purchase of Theravance makes strategic sense. He noted that Theravance has faced operational diff…